Morgan Stanley analyst James Quigley upgrades Evotec (NASDAQ:EVO) from Equal-Weight to Overweight and raises the price target from $12 to $16.
Morgan Stanley Upgrades Evotec to Overweight, Raises Price Target to $16
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.